日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVID.

一种新型PLpro抑制剂改善了新冠肺炎长期症状的临床前模型的结果

M Bader Stefanie, Calleja Dale J, Devine Shane M, Kuchel Nathan W, Lu Bernadine G C, Wu Xinyu, Birkinshaw Richard W, Bhandari Reet, Loi Katie, Volpe Rohan, Khakham Yelena, Au Amanda E, Blackmore Timothy R, Mackiewicz Liana, Dayton Merle, Schaefer Jan, Scherer Lena, Stock Angus T, Cooney James P, Schoffer Kael, Maluenda Ana, Kleeman Elizabeth A, Davidson Kathryn C, Allison Cody C, Ebert Gregor, Chen Gong, Katneni Kasiram, Klemm Theresa A, Nachbur Ueli, Georgy Smitha Rose, Czabotar Peter E, Hannan Anthony J, Putoczki Tracy L, Tanzer Maria, Pellegrini Marc, Lechtenberg Bernhard C, Charman Susan A, Call Melissa J, Mitchell Jeffrey P, Lowes Kym N, Lessene Guillaume, Doerflinger Marcel, Komander David

IL-1β drives SARS-CoV-2-induced disease independently of the inflammasome and pyroptosis signalling.

IL-1β 驱动 SARS-CoV-2 引起的疾病,与炎症小体和细胞焦亡信号无关

M Bader Stefanie, Scherer Lena, Schaefer Jan, Cooney James P, Mackiewicz Liana, Dayton Merle, Georgy Smitha Rose, Davidson Kathryn C, Allison Cody C, Herold Marco J, Strasser Andreas, Pellegrini Marc, Doerflinger Marcel

NLRP3 inflammasome-driven hemophagocytic lymphohistiocytosis occurs independent of IL-1β and IL-18 and is targetable by BET inhibitors.

NLRP3炎症小体驱动的噬血细胞性淋巴组织细胞增生症的发生与IL-1β和IL-18无关,并且是BET抑制剂的靶点

Shojaee Farzaneh, Azadian Esmaeel, Wong Min Xian, Ma Xiuquan, Rickard James, Pang Jiyi, Hall Catherine, Kueh Andrew J, Masters Seth L, Rioja Inmaculada, Prinjha Rab K, Doerflinger Marcel, Lawlor Kate E, Rashidi Maryam, Vince James E

Metabolic modeling elucidates phenformin and atpenin A5 as broad-spectrum antiviral drugs against RNA viruses.

代谢模型阐明苯乙双胍和阿替平A5是针对RNA病毒的广谱抗病毒药物

Renz Alina, Hohner Mirjam, Jami Raphaël, Breitenbach Maximilian, Josephs-Spaulding Jonathan, Dürrwald Johanna, Best Lena, Dulière Victoria, Mialon Chloé, Bader Stefanie M, Marinos Georgios, Leonidou Nantia, Cabreiro Filipe, Pellegrini Marc, Doerflinger Marcel, Rosa-Calatrava Manuel, Pizzorno Andrés, Dräger Andreas, Schindler Michael, Kaleta Christoph

Current State of Therapeutics for HTLV-1

HTLV-1 的当前治疗状况

Wang, Tiana T; Hirons, Ashley; Doerflinger, Marcel; Morris, Kevin V; Ledger, Scott; Purcell, Damian F J; Kelleher, Anthony D; Ahlenstiel, Chantelle L

A human model of Buruli ulcer: Provisional protocol for a Mycobacterium ulcerans controlled human infection study

布鲁里溃疡的人体模型:溃疡分枝杆菌控制性人体感染研究的暂行方案

Muhi, Stephen; Marshall, Julia L; O'Brien, Daniel P; Johnson, Paul D R; Ross, Gayle; Ramakrishnan, Anand; Mackay, Laura K; Doerflinger, Marcel; McCarthy, James S; Jamrozik, Euzebiusz; Osowicki, Joshua; Stinear, Timothy P

A human model of Buruli ulcer: The case for controlled human infection and considerations for selecting a Mycobacterium ulcerans challenge strain

布鲁里溃疡的人体模型:控制人体感染的必要性及选择溃疡分枝杆菌攻击菌株的考量

Muhi, Stephen; Osowicki, Joshua; O'Brien, Daniel; Johnson, Paul D R; Pidot, Sacha; Doerflinger, Marcel; Marshall, Julia L; Pellegrini, Marc; McCarthy, James; Stinear, Timothy P

Programmed cell death: the pathways to severe COVID-19?

程序性细胞死亡:导致重症新冠肺炎的途径?

Bader, Stefanie M; Cooney, James P; Pellegrini, Marc; Doerflinger, Marcel

The role of MKK4 in T-cell development and immunity to viral infections.

MKK4 在 T 细胞发育和对病毒感染的免疫中的作用

Preston Simon P, Doerflinger Marcel, Scott Hamish W, Allison Cody C, Horton Miles, Cooney James, Pellegrini Marc

BH3-only proteins: the thorny end of the ER stress response

仅含BH3结构域的蛋白质:内质网应激反应的棘手环节

Glab, Jason A; Doerflinger, Marcel; Puthalakath, Hamsa